Stonegate Capital Partners Updates Coverage on Viemed Healthcare, Inc. (VMD) 4Q 2025
Rhea-AI Summary
Viemed Healthcare (NASDAQ: VMD) reported FY25 results showing net revenue of $270.3M (up 21% y/y), net income $14.9M, and record adjusted EBITDA $61.4M. Free cash flow rose 141% y/y. Growth was driven by platform momentum, contributions from Lehan's, and stronger sleep/resupply adoption. A revised NCD added documentation and tightened coverage criteria, temporarily moderating ventilator patient growth, though reimbursement levels were unchanged and vent activity began normalizing. Management and coverage updates indicate sleep and resupply are improving recurring revenue quality and diversification of payors, while FY26 guidance and valuation suggest upside may be underappreciated.
Positive
- Revenue +21% YoY to $270.3M
- Record adjusted EBITDA of $61.4M
- Free cash flow +141% YoY
- Lehan's acquisition broadened commercial exposure and payor diversification
Negative
- Updated NCD added documentation and tightened coverage, temporarily moderating ventilator growth
- Margin mix pressure from shift toward sleep and resupply
News Market Reaction – VMD
On the day this news was published, VMD declined 4.42%, reflecting a moderate negative market reaction. Our momentum scanner triggered 8 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $16M from the company's valuation, bringing the market cap to $349M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
VMD gained 2.26% with strong volume while key peers were mixed to down (e.g., INGN -1.89%, NNOX -3.66%, OM -0.31%), suggesting a company-specific bid rather than a broad medical devices move. Only BWAY showed notable upside at about 5.33%.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Mar 04 | Share repurchase plan | Positive | -7.5% | Announced 2026 share repurchase program for up to 1,930,131 common shares. |
| Mar 04 | Full-year earnings | Positive | -7.5% | Reported record 2025 revenue, net income and Adjusted EBITDA with 2026 guidance. |
| Feb 24 | Earnings call details | Neutral | +1.8% | Announced timing and access details for Year End 2025 earnings conference call. |
| Jan 06 | Coverage initiation | Positive | +0.3% | Stonegate initiated coverage highlighting organic growth and diversified home-care platform. |
| Nov 05 | Quarterly earnings | Positive | -2.6% | Q3 2025 delivered record revenue and higher EBITDA, plus updated 2025 guidance. |
Recent positive fundamental and capital allocation news (record 2025 results, guidance, buybacks, coverage initiation) has often been followed by weak or negative next-day price reactions, indicating a pattern of the stock selling off or underperforming after good news.
Over the last few months, Viemed has reported multiple record financial results and stepped up capital returns. On Nov 5, 2025, Q3 2025 earnings showed strong revenue and cash flow, yet the stock fell. Record full-year 2025 results and 2026 guidance on Mar 4, 2026, alongside a new share repurchase program, also coincided with a -7.49% move. Stonegate’s January coverage initiation described a steadily growing in-home respiratory platform. Today’s updated coverage reiterates these 2025 achievements and business mix shifts toward sleep and resupply.
Market Pulse Summary
This announcement highlights Stonegate’s refreshed view after Viemed’s FY25 performance, including net revenue of $270.3M, net income of $14.9M, record adjusted EBITDA of $61.4M, and free cash flow up 141% year over year. The update emphasizes growth in sleep and resupply and contributions from the Lehan’s acquisition, while noting short-term friction from updated NCD requirements. Historical news flow shows recurring record results and active capital returns, making execution on FY26 guidance and regulatory dynamics key areas to watch.
Key Terms
adj. EBITDA financial
AI-generated analysis. Not financial advice.
Dallas, Texas--(Newsfile Corp. - March 11, 2026) - Viemed Healthcare, Inc. (NASDAQ: VMD). Stonegate Capital Partners Updates Coverage on Viemed Healthcare, Inc. (NASDAQ: VMD). In FY25, Viemed grew net revenue
To view the full announcement, including downloadable images, bios, and more, click here.
Key Takeaways:
- Sleep and resupply are overtaking ventilation, improving recurring revenue quality and reducing regulatory sensitivity.
- Lehan's broadens commercial exposure, diversifies payors, and creates a longer runway for scaled growth.
- Despite margin mix pressure, FY26 guidance and valuation suggest durable growth remains underappreciated.
Click image above to view full announcement.
About Stonegate
Stonegate Capital Partners is a leading capital markets advisory firm providing investor relations, equity research, and institutional investor outreach services for public companies. Our affiliate, Stonegate Capital Markets (member FINRA) provides a full spectrum of investment banking, equity research and capital raising for public and private companies.
Contacts:
Stonegate Capital Partners
(214) 987-4121
info@stonegateinc.com
Source: Stonegate, Inc.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/288110
FAQ
What were Viemed (VMD) FY25 revenue and profit figures announced March 11, 2026?
How did the updated NCD affect Viemed Healthcare (VMD) ventilator patient growth in FY25?
Why is sleep and resupply growth important for Viemed (VMD) going into FY26?
What impact did Lehan's have on Viemed Healthcare (VMD) performance and outlook?
What does Viemed's FY25 free cash flow change mean for shareholders of VMD?
Does the updated coverage note change reimbursement levels for Viemed (VMD)?
